187 related articles for article (PubMed ID: 11254898)
1. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
3. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
5. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
Levy Z; Dvir A; Shaish A; Trestman S; Cohen H; Levkovietz H; Rhachmani R; Ravid M; Harats D
Int J Exp Diabesity Res; 2003; 4(1):59-64. PubMed ID: 12745671
[TBL] [Abstract][Full Text] [Related]
6. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
[TBL] [Abstract][Full Text] [Related]
9. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
10. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
Fryer RM; Segreti J; Banfor PN; Widomski DL; Backes BJ; Lin CW; Ballaron SJ; Cox BF; Trevillyan JM; Reinhart GA; von Geldern TW
Br J Pharmacol; 2008 Mar; 153(5):947-55. PubMed ID: 18084312
[TBL] [Abstract][Full Text] [Related]
11. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
12. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
13. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
14. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis.
Ichiki T; Izumi R; Cataliotti A; Larsen AM; Sandberg SM; Burnett JC
Peptides; 2013 Oct; 48():21-6. PubMed ID: 23927843
[TBL] [Abstract][Full Text] [Related]
15. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
Hayek T; Hamoud S; Keidar S; Pavlotzky E; Coleman R; Aviram M; Kaplan M
J Cardiovasc Pharmacol; 2004 Jan; 43(1):140-7. PubMed ID: 14668580
[TBL] [Abstract][Full Text] [Related]
16. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11).
Kugiyama K; Sugiyama S; Matsumura T; Ohta Y; Doi H; Yasue H
Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):1080-7. PubMed ID: 8696950
[TBL] [Abstract][Full Text] [Related]
17. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Nawarskas J; Rajan V; Frishman WH
Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
[TBL] [Abstract][Full Text] [Related]
18. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
